Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Additional Iressa Study Closed Due To Lack Of Survival Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Data monitoring committee recommends closing National Cancer Institute-sponsored trial studying gefitinib as a maintenance therapy in non-small cell lung cancer patients who responded to chemo. NCI trial is the second study in recent months in which Iressa failed to demonstrate a survival benefit.

You may also be interested in...



AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show

Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.

AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show

Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.

Zarnestra Phase III Data Needed Pre-Approval, Oncology Committee Says

FDA's Oncologic Drugs Advisory Committee votes 7 to 4 against recommending accelerated approval of J&J's tipifarnib. Data from the Phase III trial are necessary to identify the appropriate patient population for the oncologic, members say.

Related Content

Topics

UsernamePublicRestriction

Register

PS062014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel